Guochun Liao brings over 15 years of experience leading and managing multi-discipline teams in large pharmaceutical and small biotechnology startup companies. Prior to founding IDbyDNA, he was the Vice President of Bioinformatics at Centrillion Biosciences. Before that, he was the Head of Computational Genomics and Research Biostatistics at Roche Pharmaceuticals Palo Alto site, where he was responsible for the data management and analysis for the pre-clinical and clinical projects covering a variety of disease biology and functional areas. Guochun has also served as a consulting professor at Stanford University School of Medicine. His scientific work is featured in many patents, peer reviewed publications and on the cover of scientific journals, including Science and Genome Research. Guochun holds a BS in Biophysics from the University of Science and Technology of China, and an MS in Computer Science, a Ph.D. in Genetics and an MBA from the University of California, Berkeley.
Robert Schlaberg is an Assistant Professor of Pathology at the University of Utah School of Medicine and a Medical Director at ARUP Laboratories. His research is focused on next-generation sequencing-based infectious disease diagnostics and is supported in part by the Bill & Melinda Gates Foundation. Robert co-developed Taxonomer, the metagenomics data analysis platform, utilized by IDbyDNA as its central technology. Robert received Medical degrees from the Julius-Maximilians-University in Wuerzburg, Germany and a Masters of Public Health from Columbia University where he also trained in clinical pathology and served as Chief Clinical Pathology Resident. Robert is a board certified Clinical Pathologist and Medical Microbiologist.
Mark Yandell is a recognized leader in the field of software development for comparative and functional genomics. He is a Professor of Human Genetics and H.A. & Edna Benning Presidential Endowed Chair at the University of Utah, serves as Director of the Bioinformatics program, and Co-director of the Utah Science Technology and Research Center for Genetic Discovery. In addition to developing essential algorithms for the Human Genome Project, Mark developed software at Celera Genomics used to analyze human, mouse, fruit fly, and mosquito genomes. Mark also serves as Technical Director of the Utah Genome Project, and Associate Director of the University of Utah Program in Personalized Health. Mark holds a PhD in Molecular, Cell & Developmental Biology from The University of Colorado, Boulder and completed his post-doctoral work in Computational Biology at Washington University, St. Louis.
Jeff Field brings more than 20 years of commercial leadership experience spanning the biotech, pharmaceutical, managed care, molecular diagnostics, and genetics/genomics industries. Jeff joins IDbyDNA from GenePeeks, where he served as Chief Commercial Officer. Prior to his role at GenePeeks, Jeff was the Vice President of Sales and Client Services at Foundation Medicine, where he played an instrumental role in developing the company’s commercial strategy and executing the tactical launch plan for its comprehensive tumor genomic profiling services. Before joining Foundation Medicine, Jeff held several executive level positions at Caris Life Sciences including Regional Vice President of Sales, Vice President of Oncology National Accounts, and Vice President of Strategic and Corporate Accounts where he was responsible for sales, payer relations, business development, and contracting activities. In addition, Jeff has helped to build several other disruptive, high-growth companies, including Astra Merck (now AstraZeneca) and AdvancePCS (now CVS Health). Jeff holds an MBA from Rollins College, an MS in Organic/Medicinal Chemistry from Boston College, and a BS in Chemistry from Merrimack College.
Cyrus Harmon is a co-founder and the CEO of Olema Pharmaceuticals, a drug discovery company working on novel therapeutics that target the estrogen receptor for the treatment of breast cancer. Prior to Olema Cyrus was the co-founder and CEO of Neomorphic, a pioneering bioinformatics company which was acquired by Affymetrix where he stayed on to serve as VP, Computational Genomics, and General Manager. Following his tenure at Affymetrix, Cyrus earned his PhD from the University of California, Berkeley.
Chris Fox is a commercial leader with more than 15 years of experience within the pharmaceutical, diagnostics and laboratory services industries. His expertise includes commercial strategy, market development, product management, medical marketing, thought-leader development, and genomics. Chris has a track record of launching novel technologies that have changed clinical practice globally, and has seen multiple companies through IPO and acquisitions. Prior to joining IDbyDNA Chris has worked at both publicly traded companies and startups including: Merck, Roche, Quest Diagnostics, mtm laboratories and Foundation Medicine. Chris holds a BS in Biology from Rider University and an MBA in Marketing from Texas A&M University.
Qing Li brings over 20 years of management, business development and engineering experience in the biotech and software industries. He joins IDbyDNA from Centrillion Biosciences, where he was the Senior Director of Product Marketing, responsible for consumer and bioinformatics products. He was the VP of Products at Trooval.com, a VC backed consumer internet software company. He was the Director of Business Development at Kapow Software, responsible for strategic alliances and channel sales. Previously he held management and engineering positions within leading Silicon Valley companies such as Oracle and TIBCO. He holds an MBA from the University of California at Berkeley and attended a PhD program in Computer Science at the University of California at Santa Barbara.